ISCO · International Stem Cell CORP
$0.26
-0.02 (-8.13%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These circumstances raise substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.08M
Shares
8.00M
Volume · Oct 20
26.38K
Avg daily vol (3M)
31.46K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.26
Open$0.29
Day$0.26–0.29
52W close$0.12–0.51
Avg vol 30d31K
Short int48 · 0.0% float · 1.0d
Short vol4%
DataJan 2020–Oct 2026
Filing10-Q · Aug 13
Up next
filed Aug 13, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$9.51M
Trailing 12 months
Net income (TTM)
−$582,000
Trailing 12 months
Revenue growth YoY
+9.3%
Year over year
Operating margin
-4.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
16.0%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.09M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
+73.3%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+25%
above
Price vs 50-day avg
−25%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
36%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−20%
trailing
6-month return
+63%
trailing
YTD return
+86%
this year
Relative strength
+54%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
0% holders QoQ
Insider flow
Distributing
Net -$10.5K over 90 days · 100% sells
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
1 holders — near 3-yr low, contrarian setup
Squeeze score
27
low risk · 0–100
Fundamentals
Revenue growth
+4%
Y/Y
EPS growth
−67%
Y/Y
Free cash flow
$-35.0K
Quant / Vol
risk profile
Volatility
212%
annualized · 1-yr
Max drawdown
−50%
past year
ATR
12.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+25%
Bullish
Price vs 50-day avg
−25%
Bearish
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
36%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bearish · 1 of 6
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
0% holders QoQ
Insider flow
Distributing
Net -$10.5K over 90 days · 100% sells
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr low
1 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0
Now $0 · 36%
Range high $1
vs 200-day avg +25%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ISCO
this stock
International Stem Cell CORP
|
$2.08M | +85.7% | +4.1% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$131.39B | +13.5% | +46.2% | 30.2 | 1.8% |
|
MRNA
Moderna, Inc.
|
$96.65B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.13B | +4.6% | +20.8% | 20.0 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Holders
1
- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- Accel Wealth Management
Held
Float
Short & Settlement
Smart Money
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ISCO | +2.7% | -20.3% | +62.5% | -16.1% | +85.7% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | +3.8% | -19.7% | +54.4% | -17.0% | +72.9% |